相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions
Steven K. Clinton et al.
JOURNAL OF NUTRITION (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Lei Ding et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers
Tahir Ali Chohan et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review
Aakash Deep et al.
NEW JOURNAL OF CHEMISTRY (2018)
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors
Jin-Yi Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
Sandrine Aspeslagh et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia
Peter H. Wiernik
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Prolonged and tunable residence time using reversible covalent kinase inhibitors
J. Michael Bradshaw et al.
NATURE CHEMICAL BIOLOGY (2015)
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
Xiu-Xiu Chen et al.
ONCOTARGET (2015)
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
Monica M. Mita et al.
CLINICAL BREAST CANCER (2014)
Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Tahir Chohan et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Dinaciclib for the treatment of breast cancer
Carmen Criscitiello et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
Mathew P. Martin et al.
ACS CHEMICAL BIOLOGY (2013)
Predicting the Impact of Single-Nucleotide Polymorphisms in CDK2-Flavopiridol Complex by Molecular Dynamics Analysis
N. Nagasundaram et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2013)
Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors
Farhan Ahmad Pasha et al.
JOURNAL OF MOLECULAR MODELING (2013)
An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors
Yan Li et al.
MOLECULAR BIOSYSTEMS (2013)
New Pyrazolopyrimidine Inhibitors of Protein Kinase D as Potent Anticancer Agents for Prostate Cancer Cells
Manuj Tandon et al.
PLOS ONE (2013)
Development of Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitors with Potent Anti-Toxoplasma Activity
Steven M. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Novel Synthesis of 5-Amino-3-bromo-1-(tert-butyl)-1H-pyrazole-4-carbonitrile: A Versatile Intermediate for the Preparation of 5-Amino-3-aryl-1-(tert-butyl)-1H-pyrazole-4-carboxamides
Mark A. Bobko et al.
ORGANIC LETTERS (2012)
Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
Nicholas M. Levinson et al.
PLOS ONE (2012)
The CDK inhibitors in cancer research and therapy
Jonas Cicenas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Microwave-assisted synthesis of N1-and C3-substituted pyrazolo[3,4-d]pyrimidine libraries
Nick Todorovic et al.
TETRAHEDRON LETTERS (2011)
Polo-like kinases: conservation and divergence in their functions and regulation
Vincent Archambault et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Structure-based design of a new class of highly selective pyrazolo[3,4-d]pyrimidines based inhibitors of cyclin dependent kinases
Diaa. A. Ibrahim et al.
ARKIVOC (2009)
CDK inhibitors in cancer therapy: what is next?
Marcos Malumbres et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system.: Synthesis, structure-activity relationships, and molecular modeling studies
F Da Settimo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases
JA Markwalder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
分享论文
